Particle.news
Download on the App Store
3 ARTICLES
·
2w ago

Bristol Myers Sets U.K. Price for New Schizophrenia Drug Equal to U.S., Threatens to Pull Product

The company will seek U.K. approval within weeks, tying a planned 2026 launch to acceptance of a $1,850 monthly list price.

Image
US President Donald Trump poses with HHS Secretary Robert F. Kennedy Jr., his daughter, Kick Kennedy, NIH Director Jay Bhattacharya, Administrator for the Centers for Medicare and Medicaid Services Dr. Mehmet Oz, FDA Commissioner Dr. Martin Makary, Monday, May 12, 2025, in the Oval Office following a media availability during a signing of an executive order demanding Pharma industry to cut prices at the White House (Official White House Photo by Joyce N. Boghosian)
Image

Overview

  • Bristol Myers Squibb said Cobenfy will be listed in the United Kingdom at $1,850 per month, matching its U.S. list price.
  • Chief commercialization officer Adam Lenkowsky said the company will withdraw the drug if NICE or the NHS do not accept that price.
  • Cobenfy is not yet approved in Britain, and Bristol Myers says it will file for authorization in the coming weeks with approval expected next year and launch in 2026.
  • BMS executives called on the U.K. government and health authorities to collaborate with industry and recognize the value of innovative therapies to ensure access.
  • Coverage frames the pricing stance as aligned with President Trump’s push for international price parity on medicines, citing his recent executive order and Most Favored Nation messaging.